Authors: Steve Simpson-Yap; Edward De Brouwer; Tomas Kalincik; Nick Rijke; Jan A. Hillert; Clare Walton; Gilles Edan; Yves Moreau; Tim Spelman; Lotte Geys; Tina Parciak; Clement Gautrais; Nikola Lazovski; Ashkan Pirmani; Amin Ardeshirdavanai; Lars Forsberg; Anna Glaser; Robert McBurney; Hollie Schmidt; Arnfin B. Bergmann; Stefan Braune; Alexander Stahmann; Rodden Middleton; Amber Salter; Robert J. Fox; Anneke van der Walt; Helmut Butzkueven; Raed Alroughani; Serkan Ozakbas; Juan I. Rojas; Ingrid van der Mei; Nupur Nag; Rumen Ivanov; Guilherme Sciascia do Olival; Alice Estavo Dias; Melinda Magyari; Doralina Brum; Maria Fernanda Mendes; Ricardo N. Alonso; Richard S. Nicholas; Johana Bauer; Aníbal Sebastián Chertcoff; Anna Zabalza; Georgina Arrambide; Alexander Fidao; Giancarlo Comi; Liesbet Peeters

Venue: Neurology

Type: Publication

Abstract: People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS.Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1-12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl fumarate, glatiramer acetate, interfer... (read more)

DOI: 10.1212/wnl.0000000000012753